Clinical trial · Observational
AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test
Specimen Collection Study for Cancer
NCT03688906CI-TRIAL-00056809completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenoma | Adenoma | ONTOLOGY_EXACT | 0.98 |
| Adenoma Colon | — | UNRESOLVED | — |
| Cancer Colon | — | UNRESOLVED | — |
| Cancer, Rectum | Rectal Carcinoma | ALIAS | 0.90 |
| Colo-rectal Cancer | — | UNRESOLVED | — |
| Neoplasms,Colorectal | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Polyp of Colon | — | UNRESOLVED | — |
| Polyps | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Cohort A
- description
- Blood and stool specimen collection. Study samples must be collected prior to any treatment.
- label
- Cohort B
- description
- Blood and stool specimen collection. Samples must be collected prior to performing bowel preparation for the colonoscopy.
- label
- Cohort C
- description
- Blood and stool specimen collection. Study samples must be collected prior to any treatment.
Primary outcomes (1)
- measure
- Diagnosis of colorectal cancer or advanced adenomas in patients undergoing routine screening colonoscopy, or post-colonoscopy
- timeFrame
- 6 months
- description
- Clinically annotated plasma samples from participants will undergo multi-omic analyses to characterize cell-free biomarkers.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
COHORT A Inclusion Criteria: * 50-84 years of age (inclusive) at the time of screening * Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s) * At least 7 days before but no more than 6 months after the most recent colonoscopy * Able and willing to provide blood and stool (optional) samples per protocol * Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Key Exclusion Criteria: * Personal history of colorectal cancer, colorectal adenomas (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer (other than most recent diagnosis) * Colonoscopy within the previous 9 years (other than most recent diagnosis) * Overt rectal bleeding within the previous 30 days * Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. * Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. * If female, known to be pregnant. COHORT B Inclusion Criteria: * 50-84 years of age (inclusive) at the time of screening * Planning to undergo a screening colonoscopy within 75 days after providing signed informed consent * Able and willing to provide blood and stool (optional) samples per protocol * Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Key Exclusion Criteria: * Personal history of colorectal cancer, colorectal adenoma (excluding non-adenomatous (e.g., hyperplastic polyps)) or aerodigestive tract cancer * Colonoscopy within the previous 9 years * Overt rectal bleeding within the previous 30 days * Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. * Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. * If female, known to be pregnant. COHORT C Inclusion Criteria: * At least 18 years of age (inclusive) at the time of screening * Recently diagnosed with (or strong clinical suspicion for) primary colorectal cancer or advanced adenoma with plans to surgically or endoscopically remove the target lesion(s) * At least 7 days before but no more than 6 months after the most recent colonoscopy * Able and willing to provide blood and stool (optional) samples per protocol * Able to comprehend and willing to sign and date the written informed consent document(s) and any applicable medical record release documents for the study Exclusion Criteria: * Have a medical condition which, in the opinion of the investigator, should preclude enrollment into the study. * Have participated or be currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy. * If female, be known to be pregnant.
References
Publications (1)
- RESULTPutcha G, Liu T-Y, Ariazi E, Bertin M, Drake A, Dzamba M, Hogan G, Kothen-Hill S, Liao J, Li K, Mahajan S, Palaniappan K, Sansanwal P, St John J, Ulz P, Wan N, Warsinske H, Weinberg D, Yang R, Lin J. Blood-based detection of early-stage colorectal cancer using multiomics and machine learning. [Abstract] J Clin Oncol 38 (Suppl 4): A-66, 2020.